World Journal of Oncology最新文献

{"title":"Correlation Between PIK3R1 Expression and Cell Growth in Human Breast Cancer Cell Line BT-474 and Clinical Outcomes.","authors":"Yi-Fang Tsai, Jiun-I Lai, Chun-Yu Liu, Chieh-Ning Hsi, Chih-Yi Hsu, Chi-Cheng Huang, Chin-Jung Feng, Yen-Shu Lin, Ta-Chung Chao, Jen-Hwey Chiu, Ling-Ming Tseng","doi":"10.14740/wjon1986","DOIUrl":"10.14740/wjon1986","url":null,"abstract":"<p><strong>Background: </strong>While mutations in the <i>PIK3CA</i> gene play important roles in human breast carcinogenesis, <i>PIK3R1</i> gene alterations are recognized as actionable mutations for clinical cancer treatment. We aimed to elucidate the role of PIK3R1 in cell proliferation on breast carcinoma and to correlate the PIK3R1 expression with patients' outcome using human tumor tissue arrays.</p><p><strong>Methods: </strong>Using human BT-474 (estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-high) breast carcinoma cell line as <i>in vitro</i> model, the role of PIK3R1 in cell proliferation was elucidated by knock-down of the <i>PIK3R1</i> gene (ΔPIK3R1) in this cell line. Between January 2000 to December 2015, the records of a cohort of 440 patients in our hospital were retrospectively reviewed, including patients' survival. The correlations between PIK3R1 expression and patient prognosis, such as overall survival (OS) and disease-free survival (DFS), were elucidated by human breast cancer tumor tissue array immunostaining.</p><p><strong>Results: </strong>After the <i>PIK3R1</i> gene was silenced in the BT-474 line, there was an increased cell number and a decrease in the G0G1-fraction, and increased S-fraction and the S+G2M-fraction for the ΔPIK3R1-BT-474 cell line, as compared to their cell wild type (WT) line. Western blot analysis showed that decreased PIK3R1 protein levels were accompanied by an increase of the p-AKT and p-mTOR proteins in the ΔPIK3R1-BT-474 cell line, compared to the equivalent WT line. Using a human tumor tissue array, patients with high-expressed PIK3R1 protein had better outcomes in terms of DFS and OS, compared to those with low-expressed PIK3R1 protein, when breast cancer was at an early stage (stage I/II), but not across all stages of breast cancer in human patients.</p><p><strong>Conclusions: </strong>We concluded that downregulated PIK3R1 in BT-474 cells resulted in an increased cell growth and upregulated AKT-mTOR signaling. Clinically, the high-expressed PIK3R1 protein in tumors correlates positively with patients' outcome in stage I and II breast cancer.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"131-141"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of 2021 World Health Organization Grading, Peritumoral Edema, and Radiotherapy on the Recurrence of a Grossly Resected Intracranial Meningiomas: A Ten-Year Follow-Up Study.","authors":"Alaa Alkhotani, Saleh Baeesa, Maryam Alshanqiti, Taghreed Alsinani, Ahmed Najjar, Shadi Alkhayyat, Awab Tayyib, Zayed Jastaniah, Abdulrahman J Sabbagh, Nadeem S Butt, Hussain A Alamoudi, Mohammed Alharbi, Basem Bahakeem, Maher Kurdi","doi":"10.14740/wjon1999","DOIUrl":"10.14740/wjon1999","url":null,"abstract":"<p><strong>Background: </strong>The significance of histological grading and peritumoral edema (PTE) in predicting intracranial meningioma recurrence among Saudis is often neglected. This study aimed to evaluate the impact of these factors over a 10-year follow-up period.</p><p><strong>Methods: </strong>A retrospective cohort of 124 patients with intracranial meningioma was analyzed over the period from 2011 to 2021. All patients underwent gross total resection (GTR) of the tumor. Post-surgical radiotherapy (RT) was offered to patients with grade II-III meningiomas. The impact of histological grading, PTE, and RT on the recurrence-free interval (RFI) was investigated.</p><p><strong>Results: </strong>The mean age of the patients was 49 years (range: 18 - 84), with 87 females (70.2%) and 37 males (29.8%). Most tumors (88.7%, n = 110) were supratentorial, while 11.3% (n = 14) were infratentorial. The World Health Organization (WHO) grading classified 101 tumors (81.5%) as grade I, 17 (13.7%) as grade II, and six (4.8%) patients as grade III. Grading was significantly associated with RFI (P = 0.013), with grade I meningiomas having the slowest recurrence. The overall recurrence rate was 16.9%, with 38.1% (n = 8) of grade I and 61.9% (n = 13) of grade II-III meningiomas recurring within 5 years post-GTR and RT. There was no significant difference in RFI between RT-exposed and non-exposed patients (P = 0.15). PTE was present in 76 cases (61.3%) and absent in 48 (38.7%), significantly affecting RFI (P = 0.014), with shorter RFI in PTE cases. Overall, 95.2% (n = 118) of patients survived, while 4.8% (n = 6) died; five had grade II-III, and one had grade I meningioma.</p><p><strong>Conclusions: </strong>Totally, resected intracranial meningiomas with grade II-III features and PTE were associated with earlier tumor recurrence and poorer patient survival. Post-surgical RT had an insignificant effect on the RFI.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"95-103"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Whey Protein Supplementation on Postoperative Outcomes After Gynecological Cancer Surgery: A Randomized Controlled Trial.","authors":"Wiranchana Chitti, Putsarat Insin, Nisa Prueksaritanond","doi":"10.14740/wjon1990","DOIUrl":"10.14740/wjon1990","url":null,"abstract":"<p><strong>Background: </strong>Whey protein's biochemical properties make it an ideal nutritional supplement for patients with cancer, especially in perioperative care. Thus, the present study aims to assess the efficacy of whey protein supplementation (WPS) compared to standard care in enhancing postoperative outcomes for patients undergoing comprehensive surgical staging for gynecological cancer.</p><p><strong>Methods: </strong>In an open-label, randomized controlled trial conducted at Rajavithi Hospital between November 28, 2023 and July 8, 2024, 61 patients scheduled for comprehensive surgical staging were enrolled. Participants were randomized in a 1:1 ratio to either the WPS group (n = 30) or the control group (n = 31). The WPS group received isolated whey protein powder (20 g of protein per serving), administered at 6 pm before surgery and 6 am on the first postoperative day. The control group received standard postoperative care. The primary endpoint was the length of hospital stay (LOHS), with secondary outcomes including gastrointestinal function recovery, postoperative analgesic use, complications, and potential WPS-related adverse events such as transaminitis, acute kidney injury, and electrolyte imbalances.</p><p><strong>Results: </strong>The WPS group had a significantly shorter LOHS than the control group (79.0 ± 6.7 vs. 93.3 ± 28.4 h, P = 0.021). Additionally, the WPS group demonstrated significant improvements in gastrointestinal function, with shorter times to first flatus (P < 0.001), first defecation (P = 0.013), and first ambulation (P = 0.043). No significant differences were observed between the groups regarding postoperative analgesic use or complications, including fever, nausea/vomiting, wound infection, and readmission (P > 0.05). Furthermore, no WPS-related adverse events were reported.</p><p><strong>Conclusion: </strong>The use of WPS in the perioperative operative management of gynecological cancer surgery yields promising results by significantly reducing the LOHS and accelerating the recovery of gastrointestinal function while maintaining a favorable safety profile.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"70-82"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Analysis of Anaplastic Thyroid Carcinoma With Various Therapeutic Modalities: Twenty-Seven Years' Experience in a Single Cancer Center.","authors":"Putu Anda Tusta Adiputra, I Gede Budhi Setiawan, I Putu Gede Septiawan Saputra, I Wayan Sudarsa","doi":"10.14740/wjon1988","DOIUrl":"10.14740/wjon1988","url":null,"abstract":"<p><strong>Background: </strong>Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid gland malignancy. Several consensuses support the concept of multimodal therapy that combines surgery, radiation, chemotherapy, and targeted therapy. However, patient's comorbidity, poor performance status, and metastasis often make it impossible for patients to undergo multimodal therapy. Therefore, this study aimed to evaluate the survival analysis of ATC patients with different therapeutic modalities.</p><p><strong>Methods: </strong>This study was a retrospective cohort study using data from the Cancer Registry in our institution. All patients with ATC who visited Prof Ngoerah Hospital between 1998 and 2024 were included in this study. Data regarding the survival duration of patients who received treatment modalities, and clinical data were analyzed using SPSS 20.0 with Kaplan-Meier and log-rank tests.</p><p><strong>Results: </strong>Forty-two subjects with ATC were included in the analysis, of which 57.1% were female, with a mean age of 62.57 ± 13.42 years old. The median survival is 27.5 days. This study found no association between survival time and clinical characteristics of the patients (P > 0.05). This study found that patients who received combination therapy such as surgery + chemotherapy/radiotherapy (RT) had a longer survival time (64 days), compared to other patients who received surgery only (26 days), chemotherapy/RT only (49 days), or patients who died before receiving any therapy (19 days). However, the log-rank test showed that it was not statistically different (P > 0.05).</p><p><strong>Conclusion: </strong>ATC survival rates have remained low, and aggressive strategies are still needed to improve the prognosis.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"113-119"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression Profile of Thymidine Kinase Genes in Cervical Squamous Cell Carcinoma Confirmed by Various Detection Methods.","authors":"Cai Xia Liang, Ya Jun Pang, Man Yu Chen, Long Nian Hong, Si Xia Huang, Cheng Nong Guan","doi":"10.14740/wjon1962","DOIUrl":"10.14740/wjon1962","url":null,"abstract":"<p><strong>Background: </strong>Thymidine kinases (TKs) are key enzymes involved in DNA synthesis and repair, with alterations in their expression associated with various cancers. Thymidine kinase 1 (TK1) and TK2 are cytosolic enzyme proteins that catalyze the addition of a gamma-phosphate group to thymidine. The existing literature on TK1 in cervical squamous cell carcinoma (CESC) fails to address the clinical role of TK1 overexpression and its possible molecular mechanism in CESC. The clinical significance of TK2 in CESC is also unknown. The objective was to explore the differential expression, clinical significance, and molecular mechanisms of TK1 and TK2 in CESC.</p><p><strong>Methods: </strong>The researchers collected global high-throughput data, extracted the expression levels of TK1 and TK2, and calculated the integrated standardized mean difference (SMD) and summarized receiver's operating characteristics (sROC) of TK1 or TK2 mRNA to investigate the expression profiles of TK genes fully and objectively in 918 CESC tissues and 360 control tissues. In-house tissue microarrays for immunohistochemical testing were used to verify the protein level of TK1 in 62 CESC tissues and control tissues. The growth effect of TK1 and TK2 in CESC cell lines was assessed using Chronos dependency scores derived from CRISPR knockout screen in the Achilles project. We also analyzed the potential mechanism of TK genes by studying the relationship between TK gene expression and immune infiltration, gene alternations as well as the related signal pathways.</p><p><strong>Results: </strong>The various detection methods employed all confirmed that the TK1 expression is upregulated and TK2 is downregulated in CESC tissues (SMD: 2.44, 95% confidence interval (CI): 1.36 - 3.51, area under curve (AUC): 0.88, 95% CI: 0.85 - 0.90; SMD: -0.69, 95% CI: -1.25 to -0.14, AUC: 0.75, 95% CI: 0.71 - 0.78). Inhibition of TK1 expression by CRISPR knockout had negative influence on the biological functions of 11 CESC cell lines. The expression of TK2 was negatively correlated with the malignant progression of CESC. Expression of TK genes showed significant association with the immune infiltration of macrophages, CD4⁺ T cells, and neutrophils. Genes related with TK1 or TK2 were involved in pathways related to DNA replication, proteasome, and homologous recombination.</p><p><strong>Conclusions: </strong>Clinically, these findings suggest that the differential expression of TK1 and TK2 could serve as potential biomarkers, as well as therapeutic targets for personalized treatment strategies in CESC patients.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"30-50"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylation of <i>SOX1</i> and <i>PAX1</i> Are Risk Factors and Potential Biomarkers for Cervical Lesions.","authors":"Yan Die Lin, Xiao Yue Li, Li Wei Shao, Ai Jun Liu","doi":"10.14740/wjon1985","DOIUrl":"10.14740/wjon1985","url":null,"abstract":"<p><strong>Background: </strong>The correlation between methylation of paired box gene 1 (<i>PAX1</i>) and sex determining region Y-box 1 (<i>SOX1</i>) with human papillomavirus (HPV) infection and the progression of cervical lesions is not well understood. This study aims to explore the potential value of <i>PAX1</i> and <i>SOX1</i> as diagnostic biomarkers for cervical diseases.</p><p><strong>Methods: </strong>A total of 139 cervical biopsy tissue samples were obtained from the Department of Pathology, the Seventh Medical Center, Chinese PLA General Hospital from 2021 to 2023. The samples include 32 cases of chronic cervicitis (inflammation group), 30 cases of low-grade squamous intraepithelial lesions (LSIL group), 50 cases of high-grade squamous intraepithelial lesions (HSIL group), and 27 cases of cervical squamous cell carcinoma (CSCC group). DNA was extracted from paraffin-embedded tissues, and the levels of HPV infection and methylation of <i>PAX1</i> and <i>SOX1</i> were detected.</p><p><strong>Results: </strong>The methylation index (M-index) of <i>PAX1</i> and <i>SOX1</i> in the HSIL and CSCC groups is significantly higher than in the inflammation group (both P < 0.0001), with no significant difference between the LSIL and inflammation groups. There is no significant difference in the positive <i>PAX1</i> and <i>SOX1</i> methylation rate with HPV infection and age. The positive rates of <i>PAX1</i> methylation in the inflammation, LSIL, HSIL, and CSCC groups were 3.13%, 10.00%, 44.00%, and 88.89%, respectively. The positive rates of <i>SOX1</i> methylation were 3.13%, 10.00%, 40.00%, and 77.78%, respectively, and increasing with the progression of cervical lesions (R² = 0.9189/R² = 0.9279, P < 0.0001/P < 0.0001). Comparing LSIL, HSIL, and CSCC with the inflammation group and using cervical biopsy pathology diagnosis as the gold standard, methylation of <i>PAX1</i> and <i>SOX1</i> is a risk factor for HSIL and CSCC, with odds ratio (OR) values significantly increasing as lesions progress. The sensitivity of <i>PAX1</i> and <i>SOX1</i> methylation to cervical lesions increases with the progression of the lesions.</p><p><strong>Conclusions: </strong>Methylation of <i>SOX1</i> and <i>PAX1</i> is not associated with HPV infection. The positive rate of methylation for <i>SOX1</i> and <i>PAX1</i> is positively correlated with cervical lesions, which can serve as potential biomarkers for HSIL and CSCC. They are risk factors and potential screening indicators for HSIL and above cervical lesions.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"104-112"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordant Responses Between Imaging Examination and Surgical Pathology of Head and Heck Squamous Cell Carcinoma After Neoadjuvant Immunotherapy Combined With Chemotherapy.","authors":"Yu Dong Ning, Yi Xuan Song, Yu Qin He, Han Li, Shao Yan Liu","doi":"10.14740/wjon1973","DOIUrl":"10.14740/wjon1973","url":null,"abstract":"<p><strong>Background: </strong>We here investigated the value of imaging examination in evaluating tumor remission-based surgery in patients with head and neck squamous cell carcinoma (HNSCC), who had undergone neoadjuvant immunotherapy combined with chemotherapy (NICC).</p><p><strong>Methods: </strong>HNSCC patients who underwent NICC and surgery from May 2021 to September 2023 were retrospectively analyzed. All patients had to undergo imaging examination evaluation, including enhanced computed tomography (CT) and enhanced magnetic resonance (MR) imaging before and after NICC. Data related to clinical parameters, complete response of the primary site (PrCR), complete response of the primary site and the lymph node (PLCR), complete response of the lymph node (LCR), and tumor response (TR), were gathered. The paired Chi-square test and <i>t</i>-test were conducted to analyze the differences in responses between imaging examination and pathology. Binary logistic regression was applied to analyze the relevant clinical factors of differences in responses.</p><p><strong>Results: </strong>In total, data of 41 patients were included in this study. Significant discordant responses were observed between enhanced CT, magnetic resonance imaging (MRI), and pathology in PrCR (4.9%, 7.3% vs. 41.5%), LCR (12.2%, 7.3% vs. 53.7%), PLCR (0%, 0% vs. 31.7%), and TR (severe 29.3%,17.1% vs. 25.61%) (P < 0.05). Patients with hypopharyngeal cancer (odds ratio (OR): 7.04), oral cancer (OR: 3.64), higher neutrophil to lymphocyte ratio (NLR) (OR: 2.05), and earlier T stage (OR: 0.71) exhibited a larger response difference between enhanced CT and pathology. Patients with younger age (OR: 0.79) hypopharyngeal cancer (OR: 22.81), oral cancer (OR: 2.65), higher NLR (OR: 19.47), and earlier T stage (OR: 0.29) exhibited a larger response difference between enhanced MR and pathology.</p><p><strong>Conclusions: </strong>Discordant responses were noted between the imaging examination and surgical pathology of HNSCC after NICC. Hypopharyngeal cancer, higher NLR, and earlier T stage may predict a higher response difference.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"59-69"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Clinical Outcomes of Human Epidermal Growth Factor Receptor 2 Expression in Patients With Advanced Urothelial Carcinoma.","authors":"Ivan A Ortiz-Calderon, Luis Felipe Arias-Ruiz, Rita Dorantes-Heredia, Jose Manuel Ruiz-Morales","doi":"10.14740/wjon1966","DOIUrl":"10.14740/wjon1966","url":null,"abstract":"<p><strong>Background: </strong>The prognosis for urothelial carcinoma remains poor, with limited therapeutic options, emphasizing the need for further research into targeted therapies. The prognostic and predictive significance of human epidermal growth factor receptor 2 (HER2) expression in urothelial carcinoma remains unclear, with previous studies reporting conflicting results.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of advanced urothelial carcinoma cases diagnosed between January 2017 and December 2022. HER2 status was prospectively determined using the Leica CB11 antibody on available biopsy specimens. Patient data, tumor characteristics, and survival outcomes were retrieved from hospital records for analysis.</p><p><strong>Results: </strong>Of the 84 patients initially identified with muscle-invasive disease, HER2 immunohistochemistry (IHC) was performed on 50 samples. Among these, 54% exhibited HER2 scores ≥ 1+, with 22% classified as HER2-positive (3+ score by IHC), 10% as equivocal (2+ score by IHC), and 22% as HER2-low (1+ score by IHC). The distribution of HER2 score ≥ 1+ tumors included 25.7% in the bladder, 20.0% in the renal pelvis, and none in the ureter. HER2-positive (3+ score by IHC) tumors were all histological grade 3. Among these patients, 13.4% presented with localized disease, 20% with locally advanced disease, and 50% with metastatic disease at the time of diagnosis. Notably, 42.8% of recurrent tumors originating from the renal pelvis and 62.5% of those from the bladder exhibited HER2 scores ≥ 1+. Among patients diagnosed with non-metastatic disease, 100% with renal pelvis tumors and 75% with bladder tumors experienced metastatic recurrence if they were HER2-positive (3+ score by IHC). The overall survival for HER2-negative patients was 31.0 months (95% confidence interval (CI): 15.29 - 66.70) compared to 13.0 months (95% CI: 7.32 - 18.68) in the HER2 score ≥ 1+ population (P = 0.0029).</p><p><strong>Conclusions: </strong>In this cohort of Mexican patients with urothelial carcinoma, HER2 expression was observed in 54.4% of cases. HER2-positive (+3 by IHC) tumors were associated with higher histological grade and worse prognostic outcomes, including increased recurrence, progression, and mortality.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"51-58"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activity-Regulated Cytoskeleton-Associated Protein Gene Expression Is Associated With High Infiltration of Stromal Cells and Immune Cells, but With Less Cancer Cell Proliferation and Better Overall Survival in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers.","authors":"Gabrielle Yee, Rongrong Wu, Masanori Oshi, Itaru Endo, Takashi Ishikawa, Kazuaki Takabe","doi":"10.14740/wjon1936","DOIUrl":"10.14740/wjon1936","url":null,"abstract":"<p><strong>Background: </strong>Peritumoral lidocaine infiltration prior to excision is associated with better survival in breast cancer (BC), which led us to hypothesize that innervation to the tumor affects its biology and patient survival. Activity-regulated cytoskeleton-associated protein (ARC) gene expression is known to be regulated by neuronal activity. Therefore, we studied the clinical relevance of ARC gene expression as a surrogate of neuronal activity in BC.</p><p><strong>Methods: </strong>Sweden Cancerome Analysis Network - Breast (SCAN-B (GSE96058), n = 3,273) cohort and The Cancer Genome Atlas (TCGA, n = 1,069) were analyzed.</p><p><strong>Results: </strong>High ARC expression was significantly associated with smaller tumor size, without lymph node metastasis, and less stage IV disease in one cohort, but not validated by the other. Estrogen receptor-positive (ER⁺)/human epidermal growth factor receptor 2-negative (HER2^-) and luminal A expressed significantly higher ARC compared to the other subtypes in both cohorts (P < 0.005). High ARC BC was significantly associated with lower Nottingham histological grade and lower Ki67 gene expression consistently in ER⁺/HER2^- but not triple negative breast cancer (TNBC) in both cohorts (P < 0.001). Cell proliferation-related gene sets in the Hallmark collection (E2F targets, G2M checkpoint, and mitotic spindle) were significantly enriched to low ARC BC in ER⁺/HER2^- but not TNBC in TCGA. The stromal cells (fibroblasts, vascular endothelial cells, and adipocytes) were all significantly infiltrated in high ARC ER⁺/HER2^-, but not in TNBC, except for neurons. Homologous recombination deficiency, intratumor heterogeneity, fraction altered, silent or non-silent mutation rate were all significantly lower in high ARC ER⁺/HER2^- but not TNBC. Although there was no difference in single nucleotide variant or indel neoantigens, tumor infiltrating lymphocytes, and cytolytic activity by ARC expression regardless of subtype, multiple immune cells were significantly infiltrated in high ARC ER⁺/HER2^-, including CD8, CD4 memory cells, helper type II T cells, regulatory T cells, M2 macrophages, and B cells (all P < 0.03 in both cohorts), but not in TNBC. Disease-specific and overall survival were significantly improved in high ARC ER⁺/HER2^- consistently in both cohorts (all P < 0.05), but this was not the case in TNBC.</p><p><strong>Conclusion: </strong>ARC gene expression was associated with less cancer cell proliferation, high infiltration of stromal cells and immune cells, and better survival in the ER⁺/HER2^- but not TNBC subtype.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"16-29"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>ACTR10</i> Overexpression Facilitates the Progression and Tyrosine Kinase Inhibitor Resistance in Hepatocellular Carcinoma.","authors":"Jie Luo, Kai Qin, Rong Quan He, Jian Di Li, Zhi Guang Huang, Bin Tong Yin, Tong Wu, Yu Zhen Chen, Di Yuan Qin, Jia Yuan Luo, Mei Wu, Bang Teng Chi, Gang Chen, Jian Jun Li, Yu Bin Huang","doi":"10.14740/wjon1944","DOIUrl":"10.14740/wjon1944","url":null,"abstract":"<p><strong>Background: </strong>In the present day, hepatocellular carcinoma (HCC) remains a formidable threat to human health. Actin-related protein 10 (<i>ACTR10</i>) is related to tyrosine kinase inhibitor (TKI) resistance. A comprehensive analysis of <i>ACTR10</i> in HCC will further our understanding of the molecular mechanisms underlying this resistance phenomenon, shedding light on potential therapeutic strategies for combating TKI resistance in HCC.</p><p><strong>Methods: </strong>We conducted an integration of high-throughput datasets across various centers, analyzing <i>ACTR10</i> expression using the Cancer Cell Line Encyclopedia (CCLE) and assessing its implications through clustered regularly interspaced short palindromic repeats (CRISPR) knockout screen. Pathogenic mechanisms were elucidated through enrichment analysis. Prognostic assessment utilized Kaplan-Meier survival and univariate Cox analyses. An integrated analysis of gene expression profiles related to TKI in HCC was conducted, and TKI resistance mechanisms were explored through enrichment analysis. Potential therapeutic drugs were identified using the Drug Gene Budger database and molecular docking techniques.</p><p><strong>Results: </strong>The standardized mean difference (SMD) of 0.34 (95% confidence interval (CI): 0.22 - 0.45, P < 0.05) and <i>ACTR10</i>-dependent growth in HCC cells confirm its upregulation in HCC. The area under the summary receiver operating characteristic (sROC) curve was 0.69, indicating moderate discriminative ability of <i>ACTR10</i> in HCC patients. <i>ACTR10</i> exerts its pro-cancer effect by influencing RNA splicing, mRNA processing and nucleocytoplasmic transport. A hazard ratio of 2.19 (95% CI: 1.56 - 3.08, P < 0.05) identifies <i>ACTR10</i> as an independent prognostic risk factor. Additionally, the SMD of 0.88 (95% CI: 0.01 - 0.76, P < 0.05) validates <i>ACTR10</i> as a TKI-resistance gene, mediating resistance via enhanced exocytosis, autophagy, and apoptosis in HCC patients. Trichostatin A emerges as a prospective targeted agent for HCC.</p><p><strong>Conclusion: </strong>The upregulation of <i>ACTR10</i> accelerates HCC progression, promotes TKI resistance, and emerges as a prospective target for the treatment of HCC.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"15 6","pages":"882-901"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}